Lab study hopes to stop scarring in rare autoimmune disease
NCT ID NCT07642297
First seen Jun 16, 2026 · Last updated Jun 16, 2026
Summary
This study uses blood and skin samples from 10 people with early, severe systemic sclerosis and 10 healthy volunteers to see if blocking a protein called TL1A can stop or reverse skin scarring. Researchers will test this in the lab, not on patients directly. The goal is to understand if TL1A is a good target for future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Immunorheumatology Unit, Fondazione Policlinico Universitario Campus Bio-Medico
Rome, Italy, 00128, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.